{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:17:16Z","timestamp":1793312236711,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ejmech.2021.113923","type":"journal-article","created":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T20:07:28Z","timestamp":1634587648000},"page":"113923","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Novel 5-fluorouracil sensitizers for colorectal cancer therapy: Design and synthesis of S1P receptor 2 (S1PR2) antagonists"],"prefix":"10.1016","volume":"227","author":[{"given":"Dongdong","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhikun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuecui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zirong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianjun","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuxiang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengbiao","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2021.113923_bib1","doi-asserted-by":"crossref","first-page":"107447","DOI":"10.1016\/j.pharmthera.2019.107447","article-title":"5-fluorouracil and other fluoropyrimidines in colorectal cancer: past, present and future","volume":"206","author":"Vodenkova","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2021.113923_bib2","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S0959-8049(98)00226-3","article-title":"Oral fluoropyrimidines in the treatment of colorectal cancer","volume":"34","author":"Meropol","year":"1998","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2021.113923_bib3","doi-asserted-by":"crossref","first-page":"iv22","DOI":"10.1093\/annonc\/mdx224","article-title":"Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Glynne-Jones","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2021.113923_bib4","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1200\/JCO.2008.19.5362","article-title":"Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials","volume":"27","author":"Sargent","year":"2009","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ejmech.2021.113923_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/1758834015614530","article-title":"Pharmacologic resistance in colorectal cancer: a review","volume":"8","author":"Hammond","year":"2016","journal-title":"Ther Adv Med Oncol"},{"issue":"Suppl 10","key":"10.1016\/j.ejmech.2021.113923_bib6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/annonc\/mdl280","article-title":"Chemoresistance in solid tumours","volume":"17","author":"Wilson","year":"2006","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2021.113923_bib7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/path.1706","article-title":"Molecular mechanisms of drug resistance","volume":"205","author":"Longley","year":"2005","journal-title":"J.\u00a0Pathol."},{"key":"10.1016\/j.ejmech.2021.113923_bib8","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1634\/theoncologist.7-4-288","article-title":"Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review","volume":"7","author":"Malet-Martino","year":"2002","journal-title":"Oncol."},{"issue":"Suppl 1","key":"10.1016\/j.ejmech.2021.113923_bib9","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s10120-003-0232-9","article-title":"S-1 in gastric cancer: a comprehensive review","volume":"6","author":"Maehara","year":"2003","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.ejmech.2021.113923_bib10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1124\/jpet.107.127183","article-title":"Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis","volume":"323","author":"Foster","year":"2007","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2021.113923_bib11","doi-asserted-by":"crossref","first-page":"14839","DOI":"10.1074\/jbc.M112.426726","article-title":"Sphingosine 1-phosphate (S1P) receptor agonists mediate pro-fibrotic responses in normal human lung fibroblasts via S1P2 and S1P3 receptors and Smad-independent signaling","volume":"288","author":"Sobel","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2021.113923_bib12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.cellsig.2008.07.011","article-title":"Sphingosine kinase\/sphingosine 1-phosphate signalling in central nervous system","volume":"21","author":"Okada","year":"2009","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ejmech.2021.113923_bib13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1651-2227.2007.00206.x","article-title":"Sphingosine 1-phosphate in neural signalling and function","volume":"96","author":"Milstien","year":"2007","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ejmech.2021.113923_bib14","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1164\/rccm.200804-595SO","article-title":"Sphingolipids in the lungs","volume":"178","author":"Uhlig","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejmech.2021.113923_bib15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000315109","article-title":"Endothelial functions of sphingosine-1-phosphate","volume":"26","author":"Lucke","year":"2010","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.ejmech.2021.113923_bib16","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ejphar.2008.02.089","article-title":"Sphingolipid signalling in the cardiovascular system: good, bad or both?","volume":"585","author":"Alewijnse","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113923_bib17","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2016-01-692129","article-title":"S1PR2 deficiency in DLBCL: a FOXy connection","volume":"127","author":"Baldari","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2021.113923_bib18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cellsig.2018.09.019","article-title":"S1PR2 antagonist alleviates oxidative stress-enhanced brain endothelial permeability by attenuating p38 and Erk1\/2-dependent cPLA2 phosphorylation","volume":"53","author":"Cao","year":"2019","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ejmech.2021.113923_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aav1263","article-title":"CD4 T cell sphingosine 1-phosphate receptor (S1PR)1 and S1PR4 and endothelial S1PR2 regulate afferent lymphatic migration","volume":"4","author":"Xiong","year":"2019","journal-title":"Sci Immunol"},{"key":"10.1016\/j.ejmech.2021.113923_bib20","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1182\/blood-2012-11-467191","article-title":"Critical role of sphingosine-1-phosphate receptor 2 (S1PR2) in acute vascular inflammation","volume":"122","author":"Zhang","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2021.113923_bib21","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41401-020-0460-0","article-title":"Increased S1P induces S1PR2 internalization to blunt the sensitivity of colorectal cancer to 5-fluorouracil via promoting intracellular uracil generation","volume":"42","author":"Zhang","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2021.113923_bib22","doi-asserted-by":"crossref","first-page":"104717","DOI":"10.1016\/j.phrs.2020.104717","article-title":"S1PR2 inhibitors potently reverse 5-FU resistance by downregulating DPD expression in colorectal cancer","volume":"155","author":"Zhang","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2021.113923_bib23","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1124\/jpet.107.121210","article-title":"Sphingosine 1-phosphate has dual functions in the regulation of endothelial cell permeability and Ca2+ metabolism","volume":"323","author":"Itagaki","year":"2007","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2021.113923_bib24","doi-asserted-by":"crossref","first-page":"21453","DOI":"10.1074\/jbc.C200176200","article-title":"The immune modulator FTY720 targets sphingosine 1-phosphate receptors","volume":"277","author":"Brinkmann","year":"2002","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2021.113923_bib25","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1126\/science.1070238","article-title":"Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists","volume":"296","author":"Mandala","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2021.113923_bib26","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jns.2008.06.031","article-title":"Central nervous system-directed effects of FTY720 (fingolimod)","volume":"274","author":"Miron","year":"2008","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.ejmech.2021.113923_bib27","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1177\/1352458512438723","article-title":"FTY720 on the way from the base camp to the summit of the mountain: relevance for remyelination","volume":"18","author":"Kipp","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.ejmech.2021.113923_bib28","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.bmcl.2015.02.029","article-title":"Discovery of novel S1P2 antagonists. Part 1: discovery of 1,3-bis(aryloxy)benzene derivatives","volume":"25","author":"Kusumi","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113923_bib29","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1016\/j.bmcl.2015.09.022","article-title":"Discovery of novel S1P2 antagonists. Part 2: improving the profile of a series of 1,3-bis(aryloxy)benzene derivatives","volume":"25","author":"Kusumi","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113923_bib30","doi-asserted-by":"crossref","first-page":"7928","DOI":"10.1039\/C5OB00951K","article-title":"A\u00a0potent and selective C-11 labeled PET tracer for imaging sphingosine-1-phosphate receptor 2 in the CNS demonstrates sexually dimorphic expression","volume":"13","author":"Yue","year":"2015","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2021.113923_bib31","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.bmcl.2016.01.031","article-title":"Discovery of novel S1P2 antagonists, part 3: improving the oral bioavailability of a series of 1,3-bis(aryloxy)benzene derivatives","volume":"26","author":"Kusumi","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113923_bib32","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.bmcl.2017.12.010","article-title":"Design and synthesis of pyrazolopyridine derivatives as sphingosine 1-phosphate receptor 2 ligands","volume":"28","author":"Luo","year":"2018","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113923_bib33","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1016\/j.bmc.2019.06.047","article-title":"Design, synthesis, and in\u00a0vitro bioactivity evaluation of fluorine-containing analogues for sphingosine-1-phosphate 2 receptor","volume":"27","author":"Luo","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113923_bib34","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.1021\/acs.jmedchem.5b00085","article-title":"Potent and nontoxic chemosensitizer of P-Glycoprotein-Mediated multidrug resistance in cancer: synthesis and evaluation of methylated epigallocatechin, gallocatechin, and dihydromyricetin derivatives","volume":"58","author":"Wong","year":"2015","journal-title":"J.\u00a0Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421007728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421007728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:33:35Z","timestamp":1759329215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421007728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":34,"alternative-id":["S0223523421007728"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113923","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel 5-fluorouracil sensitizers for colorectal cancer therapy: Design and synthesis of S1P receptor 2 (S1PR2) antagonists","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113923","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113923"}}